Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) Sees Significant Decline in Short Interest

Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) saw a significant decrease in short interest during the month of May. As of May 15th, there was short interest totaling 670,614 shares, a decrease of 77.9% from the April 30th total of 3,038,967 shares. Currently, 6.4% of the company’s shares are sold short. Based on an average trading volume of 2,410,748 shares, the days-to-cover ratio is currently 0.3 days.

Institutional Investors Weigh In On Calidi Biotherapeutics

Several institutional investors and hedge funds have recently modified their holdings of CLDI. Virtu Financial LLC purchased a new stake in shares of Calidi Biotherapeutics in the fourth quarter worth about $25,000. Warberg Asset Management LLC purchased a new stake in shares of Calidi Biotherapeutics in the third quarter worth about $28,000. Geode Capital Management LLC boosted its holdings in Calidi Biotherapeutics by 41.7% in the fourth quarter. Geode Capital Management LLC now owns 41,929 shares of the company’s stock valued at $49,000 after purchasing an additional 12,334 shares during the last quarter. Finally, DRW Securities LLC purchased a new position in Calidi Biotherapeutics in the fourth quarter valued at about $173,000. Hedge funds and other institutional investors own 12.53% of the company’s stock.

Calidi Biotherapeutics Trading Down 2.6%

NYSEAMERICAN:CLDI traded down $0.01 on Friday, hitting $0.19. 1,508,070 shares of the stock were exchanged, compared to its average volume of 2,279,656. The stock has a market cap of $3.57 million, a PE ratio of -0.04 and a beta of 1.31. The company has a current ratio of 1.92, a quick ratio of 1.92 and a debt-to-equity ratio of 0.15. The stock has a fifty day moving average of $0.23 and a 200-day moving average of $0.77. Calidi Biotherapeutics has a fifty-two week low of $0.16 and a fifty-two week high of $19.20.

Calidi Biotherapeutics (NYSEAMERICAN:CLDI) last issued its earnings results on Thursday, May 14th. The company reported ($0.43) earnings per share for the quarter.

About Calidi Biotherapeutics

Calidi Biotherapeutics is a clinical-stage biotechnology company focused on the development of targeted immunotherapies that harness the body’s innate immune system to treat cancer and infectious diseases. By delivering proprietary RNA-based immune stimulants directly into the tumor microenvironment or sites of infection, Calidi aims to trigger a robust local immune response while minimizing systemic toxicity. The company’s platform is designed to engage multiple innate immune pathways, including toll-like receptors and RIG-I-like receptors, to initiate durable antitumor and antiviral activity.

Calidi’s lead oncology programs include CB-012, an intravesical therapy in clinical development for non-muscle invasive bladder cancer, and CB-013, an intratumoral candidate targeting a range of advanced solid tumors.